摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-2-hydroxy-2-(p-tolyl)acetic acid | 75172-62-2

中文名称
——
中文别名
——
英文名称
(S)-2-hydroxy-2-(p-tolyl)acetic acid
英文别名
(S)-(+)-p-methylmandelic acid;(S)-4-methylmandelic acid;(2S)-2-hydroxy-2-(4-methylphenyl)acetic acid
(S)-2-hydroxy-2-(p-tolyl)acetic acid化学式
CAS
75172-62-2
化学式
C9H10O3
mdl
——
分子量
166.177
InChiKey
SFGURAWGCAPHON-QMMMGPOBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    57.5
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • The Synthesis of Chiral α-Aryl α-Hydroxy Carboxylic Acids via RuPHOX-Ru Catalyzed Asymmetric Hydrogenation
    作者:Huan Guo、Jing Li、Delong Liu、Wanbin Zhang
    DOI:10.1002/adsc.201700846
    日期:2017.10.25
    A ruthenocenyl phosphino‐oxazoline‐ruthenium complex (RuPHOX−Ru) catalyzed asymmetric hydrogenation of α‐aryl keto acids has been successfully developed, affording the corresponding chiral α‐aryl α‐hydroxy carboxylic acids in high yields and with up to 97% ee. The reaction could be performed on a gram scale with a relatively low catalyst loading (up to 5000 S/C) and the resulting products can be transformed
    已成功开发了钌烯基膦基-恶唑啉-钌络合物(RuPHOX-Ru)催化的α-芳基酮酸不对称氢化反应,可提供高收率和ee高达97%的相应手性α-芳基α-羟基羧酸。该反应可以在相对较低的催化剂负载量(至多5000 S / C)下以克为单位进行,所得产物可以转化为几种手性结构单元,生物活性化合物和手性药物。
  • NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR
    申请人:Khile Anil Shahaji
    公开号:US20130165696A1
    公开(公告)日:2013-06-27
    Provided herein are novel processes for the preparation of phenylcyclopropylamine derivatives, which are useful intermediates in the preparation of triazolo[4,5-d]pyrimidine compounds. Provided particularly herein are novel, commercially viable and industrially advantageous processes for the preparation of a substantially pure ticagrelor intermediate, trans-(1R,2S)-2-(3,4-difluorophenyl)-cyclopropylamine. Provided further herein are novel acid addition salts of trans-(1R,2S)-2-(3,4-difluorophenyl)-cyclopropylamine, and process for their preparation. The intermediate and its acid addition salts are useful for preparing ticagrelor, or a pharmaceutically acceptable salt thereof, in high yield and purity.
    本文提供了一种制备苯基环丙胺衍生物的新型工艺,这些衍生物在三唑并[4,5-d]嘧啶化合物的制备中是有用的中间体。特别提供了一种新颖、商业可行且在工业上具有优势的工艺,用于制备一种基本纯的替卡格雷中间体,即trans-(1R,2S)-2-(3,4-二氟苯基)-环丙胺。此外,本文还提供了trans-(1R,2S)-2-(3,4-二氟苯基)-环丙胺的新型酸加盐,以及其制备工艺。该中间体及其酸加盐对于高产率和纯度制备替卡格雷或其药用可接受盐是有用的。
  • [EN] ENANTIOMERIC RESOLUTION METHOD<br/>[FR] PROCÉDÉ DE RÉSOLUTION ÉNANTIOMÉRIQUE
    申请人:PULMAGEN THERAPEUTICS INFLAMMATION LTD
    公开号:WO2011015868A1
    公开(公告)日:2011-02-10
    A method for the preparation of pioglitazone O,O'-dibenzoyl-L-tartrate wherein the content by weight of pioglitazone consists of at least 95 % by weight of the 5R enantiomer and less than 5 % of the 5S enantiomer, which method comprises: (1a) adding seed crystals of 5R- pioglitazone O,O'-dibenzoyl-l-tartrate to a rnethanol-water solution of racemic pioglitazone hydrochloride and O,O'-dibenzoyI-L-tartaric acid, thereby precipitating pioglitazone O,O'- dibenzoyl-L-tartrate;(1b) recovering said precipitate from step (1a); (1c) forming a solution of the precipitate from step (1b) in a solvent mixture of methanol, acid and water and mixing into to the resultant solution seed crystals of 5R-pioglitazone O,O'-dibenzoyl-L-tartrate, thereby precipitating pioglitazone O,O'-dibenzoyl-L-tartrate; (1d) recovering said precipitate from step (1c); (1e) repeating steps (1c) and (1d), the recovered product being the desired pioglitazone O,O'-dibenzoy! tartrate wherein the content by weight of pioglitazone consists of at least 95 % by weight of the 5R enantiomer and less than 5 % of the 5S enantiomer. Also disclosed is a modification of the method in which step 1(e) is omitted.
    一种制备吡格列酮O,O'-双苯甲酰-L-酒石酸盐的方法,其中吡格列酮的重量含量至少为其5R对映体的95%重量,5S对映体的含量少于5%,该方法包括:(1a)将5R-吡格列酮O,O'-双苯甲酰-L-酒石酸晶种加入到外消旋吡格列酮盐酸盐和O,O'-双苯甲酰-L-酒石酸的甲醇-水溶液中,从而沉淀吡格列酮O,O'-双苯甲酰-L-酒石酸盐;(1b)从步骤(1a)中回收所述沉淀物;(1c)在甲醇、酸和水的溶剂混合物中形成步骤(1b)中的沉淀物的溶液,并将5R-吡格列酮O,O'-双苯甲酰-L-酒石酸晶种混入到所得溶液中,从而沉淀吡格列酮O,O'-双苯甲酰-L-酒石酸盐;(1d)从步骤(1c)中回收所述沉淀物;(1e)重复步骤(1c)和(1d),回收的产品即为所需的吡格列酮O,O'-双苯甲酰-L-酒石酸盐,其中吡格列酮的重量含量至少为其5R对映体的95%重量,5S对映体的含量少于5%。还揭示了一种修改该方法的步骤,其中省略了步骤1(e)。
  • NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES
    申请人:Khile Anil Shahaji
    公开号:US20130150577A1
    公开(公告)日:2013-06-13
    Provided herein is a novel process for the preparation of phenylcyclopropylamine derivatives, which are useful intermediates in the preparation of triazolo[4,5-d]pyrimidine compounds. Provided particularly herein is a novel, commercially viable and industrially advantageous process for the preparation of a substantially pure ticagrelor intermediate, trans-(1R,2S)-2-(3,4-difluorophenyl)-cyclopropylamine. The intermediate is useful for preparing ticagrelor, or a pharmaceutically acceptable salt thereof, in high yield and purity.
    本文提供了一种新颖的制备苯基环丙胺衍生物的过程,这些衍生物在三唑并[4,5-d]嘧啶化合物的制备中是有用的中间体。特别提供了一种新颖的、商业可行且在工业上具有优势的过程,用于制备一种基本纯净的替卡格雷中间体,即trans-(1R,2S)-2-(3,4-二氟苯基)-环丙胺。该中间体可用于高产率和纯度地制备替卡格雷或其药学上可接受的盐。
  • [EN] PROCESS FOR PRODUCTION OF (S)-(TETRAHYDROFURAN-3-YL)HYDRAZINE<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE (S)-(TÉTRAHYDROFURANN-3-YL)HYDRAZINE
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2016021192A1
    公开(公告)日:2016-02-11
    A process for production of (S)-(tetrahydrofuran-3-yl)hydrazine of formula I or an acid addition salt thereof, comprising hydrolysis or hydrogenation step of protected hydrazine compound of formula VII, wherein Ra is a tert-butyl group or a benzyl group, is disclosed. (S)-(Tetrahydrofuran-3-yl)hydrazine of formula I or an acid addition salt thereof is a useful intermediate in the preparation of a PDE9 inhibitor.
    揭示了一种生产(S)-(四氢呋喃-3-基)肼的方法,其化学式为I或其酸盐,包括对化学式VII的保护肼化合物进行水解或氢化步骤,其中Ra是叔丁基或苄基。化学式I的(S)-(四氢呋喃-3-基)肼或其酸盐是制备PDE9抑制剂时的有用中间体。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐